Kornimate/medical-research-clean huggingface dataset:
the use of antiarrhythmic drugs in pediatrics

Conditions: Antiarrhythmic Drug Adverse Reaction

Summary: a study on the use of antiarrhythmic drugs in pediatric age group, in assiut university children's hospital, a clinical audit

arrhythmias occur in children and adolescents with congenital heart disease as well as those with structurally normal hearts. rhythm disturbances (arrhythmias) are not uncommon in sick children admitted in pediatric intensive care unit. these occur as a result of abnormalities in, or insults to, the cardiac conduction system or heart tissues. a rhythm disturbance in a child should be treated as life threatening emergency. the generation of the action potential and the regional differences that are observed throughout the heart are the result of the selective permeability of ion channels distributed on the cell membrane. abnormalities in surface membrane ion channel function are central to arrhythmogenesis. antiarrhythmic medications primarily affect the ion channels in cardiac myocytes that are responsible for generating currents that create the action potential. by altering the activity of these ion channels, the action potential is changed to reduce the likelihood of sustained arrhythmias. these drugs are predominantly used in treatment of arrhythmia but in addition they are also used as a treatment of other cardiac and non-cardiac conditions. for example, calcium channel blockers have been one of the most widely used classes of antihypertensive agents in the last 20 years. carvedilol (a beta blocker agent) can be safely used for treatment of chronic heart dysfunction in pediatric patients with dilated cardiomyopathy. β-blockers are also an essential component of pharmacologic therapy for children with congestive heart failure. there is a wide range of antiarrhythmic drugs used in treatment of arrhythmias. the modernized comprehensive classification of both established and potential antiarrhythmic drugs was proposed in 2018 class 0: hcn channel-mediated pacemaker current (if) block class i: antiarrhythmic that affect sodium channels (slow depolarization) class ii: drugs that counteract the sympathetic nervous system, predominantly beta-blockers class iii: drugs that affect the potassium channels (prolong repolarization) class iv: drugs that affect calcium channels (calcium channel blockers) class v: mechanically sensitive ion channels, mechanosensitive channel blockers class vi: gap junction channel blockers class vii: upstream target modulators. in this study the aim is to describe the use of cardiovascular drugs in pediatric cardiology unit assiut university. as regard: indications of use, proper dosage and proper management of side effects of their use.

Eligibility criteria:
inclusion criteria: * all patients with arrhythmic cardiac diseases admitted at cardiology unit assiut university hospital aged from 1 month to 18 years. * all patient receiving antiarrhythmic drugs admitted to assiut university hospital for children. exclusion criteria: • any patient on drugs other than antiarrhythmics.
lipid profile of tenon's capsule

Conditions: Glaucoma

Summary: the purpose of this study is to provide data on the lipid profile of the tenon's capsule in human glaucomatous eyes and to establish possible relationships with the short term outcome of filtration surgery.


Eligibility criteria:
inclusion criteria: * glaucoma * eligibility for surgery exclusion criteria: * patients without glaucoma

Keywords: glaucoma tenon's capsule lipid profile assessment of lipid profile in tenon's capsule in patients with glaucoma
feasibility and efficacy of remotely monitored home-based listening to preferred music for pain in older adults with low back pain

Conditions: Lower Back Pain

Summary: the purpose of this study is to examine the feasibility and acceptability of listening to 20 minutes of preferred style of music twice-daily for 4 consecutive days on pain among 20 community-dwelling older adults with lower back pain (lbp)


Eligibility criteria:
inclusion criteria: * self-report of lower back pain (lbp) * lbp in the past 3 months with an average rating of at least 30 on a 0 - 100 nrs for pain * intact cognition * no plans to change their pain medication regimens during the study time * can read and understand english * can travel to the study center * agree to sign an informed consent exclusion criteria: * deaf or have severe hearing loss * pregnant or lactating * have an implantable pain-reducing device * history of hospitalization within the preceding year for psychiatric illness * diagnosis of raynaud's disease * have a functional limitation that requires the use of an ambulatory aid such as a cane, walker, or wheelchair * history of brain surgery, brain tumor, or stroke * severe depression (promis depression t-score ≥ 70) (kroenke et al., 2020) * severe anxiety (promis anxiety ≥ 70) (american psychiatric association, 2013) * mini-mental state examination score less than 24 (creavin, wisniewski, noel-storr, et al., 2016)
compassionate use of tetrabenazine in the treatment of abnormal movements

Conditions: Hyperkinetic Movement Disorders

Summary: although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the u.s. the drug must be obtained from cambridge laboratories, the distributor, using an individual ind (#16,161). the cost of the drug is passed on to the patient. the purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

the purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

Eligibility criteria:
inclusion criteria: * subjects evaluated here at baylor in the pdcmdc demonstrating need for tetrabenazine treatment. * willing to sign informed consent. * willing to comply with procedures required as part of this study. exclusion criteria: * those subjects unwilling to comply with study requirements. * subjects unable to give informed consent.

Keywords: chorea dyskinesia hyperkinetic
the neural correlates of cannabis use

Conditions: Cannabis Dependence; Healthy

Summary: the purpose of this research study is to determine the temporal course of recovery of cb1r availability and neural oscillations, in cannabis-dependent individuals at baseline, following 48 hour confirmed inpatient abstinence and after four weeks confirmed abstinence. this research will also examine associations between cb1r availability, neural oscillations and cognitive function.

the purpose of this research study is to determine the temporal course of recovery of cb1r availability and neural oscillations, in cannabis-dependent individuals at baseline, following 48 hour confirmed inpatient abstinence and after four weeks confirmed outpatient abstinence (confirmed by tracking creatinine adjusted urine thc-cooh levels). this research will also examine associations between cb1r availability, neural oscillations and cognitive function using \[11-c\]omar pet imaging and electroencephalography.

Eligibility criteria:
inclusion criteria: cannabis dependent subjects * current cannabis consumption * willing to abstain from cannabis use for four weeks inclusion criteria for healthy controls * no current cannabis consumption exclusion criteria: * mri metal exclusions and claustrophobia * education completed is less than 12 years

Keywords: healthy control, cannabis, dependence
reliability of the 4 metre gait speed in idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this study is investigating the reliability of the 4 metre gait speed test (4mgs) in patients with a lung disease called idiopathic pulmonary fibrosis (ipf).

this observational study is investigating a simple test of walking speed, measured using the 4 metre gait speed test (4mgs), in patients with a lung disease called idiopathic pulmonary fibrosis (ipf). drug development for this disease is slow in part because there is a lack of reliable measurements that can assess effectiveness of treatment. slow walking speed has been shown to relate to poor outcomes in older adults and people with another lung disease called chronic obstructive pulmonary disease (copd. the investigators are interested to see whether usual walking speed is a reliable measure in patients with ipf as this will help inform us of its potential use as an outcome measure. to do this, participants who consent to taking part in the study will be timed walking at their usual walking speed over a distance of 4 metres (13.12 feet). participants will be asked to do this twice with a rest in between if required. one week later, participants will be asked to repeat the walking tests again.

Eligibility criteria:
inclusion criteria: * ipf diagnosis according to nice guidelines * provision of informed consent exclusion criteria: * significant co-morbidities that would limit walking ability, exercise capacity or make exercise unsafe (e.g. unstable ischaemic heart disease, neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation) * any patient whom the chief investigator feels it is unsafe to exercise (e.g. unstable cardiovascular disease) * any condition that precludes providing informed consent e.g. cognitive impairment or poor english

Keywords: gait speed functional outcome measure
bioavailability study of odm-201 in subjects with metastatic chemotherapy-naive castration-resistant prostate cancer

Conditions: Prostate Cancer

Summary: a study to investigate which of two different tablet formulations of odm-201 is best suited for use in the further development of the compound in the treatment of metastatic chemotherapy-naive castration-resistant prostate cancer. patients successfully completing the bioavailability study will be able to receive further treatment with the current capsule formulation of odm-201 until progression of their disease with the safety and tolerability of odm-201 being assessed throughout.


Eligibility criteria:
inclusion criteria: * written informed consent (ic) obtained. * histologically confirmed adenocarcinoma of prostate * progressive metastatic disease * ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (lhrh) analogue or antagonist or bilateral orchiectomy * adequate bone marrow, hepatic and renal function * able to swallow the odm-201 whole as a capsule or tablet. exclusion criteria: * previous chemotherapy for prostate cancer. * known metastases in the brain. * history of other malignancy within the previous 5 years, except a basal cell carcinoma of skin. * known gastrointestinal condition that can significantly affect the absorption of the study treatment.
comparison of i.v. ctap201 and doxercalciferol (hectorol) in subjects with chronic kidney disease (ckd) and secondary hyperparathyroidism (shpt)

Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism; Chronic Renal Insufficiency; Chronic Renal Failure

Summary: this study will compare ctap201 with doxercalciferol in patients with chronic kidney disease (ckd) and secondary hyperparathyroidism (shpt), undergoing regular hemodialysis, at different dose strengths. this study will also investigate the levels of ctap201 in the body over time and determine the safety of ctap201.


Eligibility criteria:
inclusion criteria: * body mass index between 18 and 40 * on maintenance hemodialysis three times per week * visit 1: serum ipth value greater than or equal to 200 pg/ml and lower than or equal to 1000 pg/ml * visit 1: serum total calcium value greater than 8.4 mg/dl and lower than 10.0 mg/dl * visit 1: serum phosphorus value greater than or equal to 2.5 mg/dl and lower than or equal to 5.5 mg/dl * serum 25-hydroxyvitamin d level greater than or equal to 15 ng/ml * visit 2: serum ipth value greater than 300 pg/ml * visit 2: serum ca x p product less than 56 \[mg/dl\]2 * willing and able to discontinue vitamin d and/or bone metabolism therapy for at least 2 weeks prior to administration of study drug, and length of study exclusion criteria: * taking cytochrome p450 3a inhibitors and/or inducers * abnormal liver functions

Keywords: parathyroid diseases renal insufficiency kidney failure, chronic hyperparathyroidism, secondary vitamin d hyperparathyroidism renal insufficiency, chronic kidney diseases kidney failure
study of at-527 in healthy and hcv-infected subjects

Conditions: Chronic Hepatitis C; Hepatitis C; Hepatitis C, Chronic

Summary: this study has multiple parts. it will assess the safety, tolerability and pharmacokinetics (pk) of at-527 in healthy subjects and subjects infected with hepatitis c virus (hcv). in addition, the study will assess the antiviral activity of at-527 in subjects infected with hcv.


Eligibility criteria:
inclusion criteria: all subjects (healthy and hcv-infected subjects): * must agree to use two methods of birth control from screening through 90 days after administration of the last dose of study drug * must have a negative pregnancy test at screening and prior to dosing * minimum body weight of 50 kg * willing to comply with the study requirements and to provide written informed consent additional inclusion criteria for hcv-infected subjects: * must have not received prior treatment for hcv infection * documented clinical history compatible with chronic hcv infection * plasma hcv rna ≥ 5.0 log10 iu/ml at screening. exclusion criteria: all subjects (healthy and hcv-infected subjects): * pregnant or breastfeeding * infected with hepatitis b virus or hiv * abuse of alcohol or drugs * use of other investigational drugs within 28 days of dosing * other clinically significant medical conditions or laboratory abnormalities

Keywords: hcv hepatitis c virus rna viruses flavivirus liver diseases hepatitis, viral, human flaviviridae infections
cognitive behavioral therapy in helping patients with acute myeloid leukemia or lymphoma with cancer-related fatigue

Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Cancer Fatigue; Lymphoma; Secondary Acute Myeloid Leukemia

Summary: this trial studies how well cognitive behavioral therapy works in helping patients with acute myeloid leukemia or lymphoma with cancer-related fatigue. behavioral therapy uses methods to help patients change the way they think and act. behavioral skills may help patients with acute myeloid leukemia or lymphoma cope with anxiety, depression, and other factors that may influence their level of cancer-related fatigue.

primary objectives: i. to determine whether acute myeloid leukemia (aml) and lymphoma patients with cancer-related fatigue (crf) will be satisfied with the cognitive behavioral therapy (cbt) intervention, and if cbt will be feasible for aml and lymphoma patients with crf where the feasibility will be based on adherence measurement. secondary objectives: i. to examine the preliminary effects of cbt on improvement of crf (functional assessment of cancer illness therapy (facit-f) - fatigue subscale, its related symptoms, m.d. anderson symptom inventory - acute myeloid leukemia / myelodysplastic syndromes (mdasi-aml/mds), pittsburgh sleep quality index (psqi), hospital anxiety depression scale (hads), and quality of life (fact-g) in aml and lymphoma patients receiving this combination regimen at the end of 8 weeks or 6 months. exploratory objectives: i. to explore the effects of cbt on hope for future and burdens of treatment and their interference with patients' lives using the herth hope index (hhi), and mdasi-aml/mds. outline: patients undergo cbt consisting of 7 counseling sessions, up to 45 minutes each over the phone.

Eligibility criteria:
inclusion criteria: * diagnosis of aml or aml secondary to mds (myelodysplastic syndrome) and lymphoma with fatigue \>= 4/10 (0-10 scale) on the mdasi-aml/mds. * presence of fatigue for at least 2 weeks. * normal cognition by memorial delirium assessment scale score of \< 13 at baseline. * hemoglobin \> 8 g/l within 2 weeks of enrollment in the study; if the patient has not had blood drawn for a hemoglobin level in the past two weeks, one will be done to determine the eligibility. * zubrod performance status =\< 2. * able to communicate in english or spanish. * seen at leukemia and lymphoma clinics at university of texas (ut) md anderson cancer center, houston, texas and its affiliates in university of texas. exclusion criteria: * has received cbt (cognitive behavioral therapy) for any indication (e.g. depression, sleep disturbance) in the past 1 year. * inability to comply with study protocol procedures. * prior cancer diagnosis other than noted in the inclusion criterion #1.
the use of perfusion ct derived parameters as early acute pancreatitis severity biomarker compared to clinico biological score

Conditions: Acute Pancreatitis

Summary: the investigators to establish whether early microvascular permeability parameter evaluated by perfusion-ct could be good biomarkers for severity in acute pancreatitis. therefore the investigators want to compare 48 hours-clinico-biological systemic inflammatory response syndrome score to initial microvascular permeability parameters ( ktrans - capillary membrane permeability factor- and pancreatic blood flow ) calculated by olea software using inclusion perfusion ct.


Eligibility criteria:
inclusion criteria: * patient with acute pancreatitis (based on the atlanta definition). exclusion criteria: * patient under 18 yearras old * contraindication of injection of iodinated contrast medium * pregnancy
eus guided hva and pva for circulating tumor dna in patients

Conditions: Circulating Tumor Cell; Gastrointestinal Cancer

Summary: the discovery of cell-free circulating tumor dna (crdna) in blood and the maturation of technologies for ctdna analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics. the investigators plan to perform eus-guided portal vein and hepatic vein aspiration in gi cancers patients. the aim of the current study is thus to examine the concentration of ctdna in portal vein (eus-guided pva), hepatic vein (eus-guided hva) and peripheral blood to understand the first pass effect of the liver with gastrointestinal (gi) cancers, and the possibility of using ctdna as a marker for preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for recurrence.

the discovery of cell-free circulating tumor dna (crdna) in blood and the maturation of technologies for ctdna analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics. the investigators plan to perform eus-guided portal vein and hepatic vein aspiration in gi cancers patients. the aim of the current study is thus to examine the concentration of ctdna in portal vein (eus-guided pva), hepatic vein (eus-guided hva) and peripheral blood to understand the first pass effect of the liver with gastrointestinal (gi) cancers, and the possibility of using ctdna as a marker for preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for recurrence.

Eligibility criteria:
inclusion criteria: 1. age \>= 18 years old 2. newly diagnosed stage ii-iv distal gastric cancer, pancreatic cancer or colorectal cancer 3. undergoing treatment with either: 1. surgery 2. neoadjuvant chemotherapy 3. neoadjuvant chemoirradiation 4. palliative chemotherapy/ immunotherapy exclusion criteria: 1. synchronous cancer of other sites 2. cardia, high lesser curve tumors, oesophagogastric junction tumors 3. presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear eus puncture site to portal vein and hepatic vein 4. patients with coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/ul 5. patients unwilling to undergo follow-up assessments 6. patients with liver cirrhosis, portal hypertension and/ or gastric varices 7. patient refusal to participate -

Keywords: circulating tumor cell gastrointestinal cancer endoscopic ultrasound portal vein aspiration
extension study for 2993-112

Conditions: Type 2 Diabetes Mellitus

Summary: this multicenter, open-label extension study of protocol 2993-112 is designed to assess long-term glucose control as measured by hba1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects treated with metformin who receive subcutaneously injected ac2993 (10 mcg) administered twice daily. subjects completing protocol 2993-112 are eligible to enroll.


Eligibility criteria:
all of the following criteria are to be fulfilled for inclusion of an individual in the study unless the sponsor grants an exception: * has completed the 30-week triple-blind treatment initiation/active treatment periods in protocol 2993-112, including all procedures required at the study termination visit (week 30). * male or female. female individuals must be either 1) postmenopausal as documented by serum fsh measurement unless using estrogen for hormone replacement therapy; or 2) of childbearing potential and used appropriate contraceptive methods (surgical sterility or oral, injected, barrier, intrauterine, or implanted contraceptives) for the duration of protocol 2993-112. this individual must have a current, negative pregnancy test (human chorionic gonadotropin \[hcg\], beta subunit) regardless of birth control method used. the individual agrees to continue using birth control throughout the study to prevent pregnancy. * able to understand and sign a protocol 2993-112e-specific informed consent form, communicate with the investigator, and understand and comply with the protocol requirements. individuals meeting any of the following criteria are to be excluded from the study unless the sponsor grants an exception: * has not completed protocol 2993-112. * female individuals who are pregnant, lactating, or planning to become pregnant.
hbrn: immune regulation and costimulation in natural history and therapeutic outcome of chronic hepatitis b

Conditions: Hepatitis B

Summary: this is an ancillary to the niddk-sponsored treatment trials titled: combination therapy of pegylated interferon alfa-2a and tenofovir versus tenofovir monotherapy in chronic hepatitis b (nct01369212) and combination entecavir and peginterferon therapy in hbeag-positive immune-tolerant adults with chronic hepatitis b (nct01369199). this study will examine the balance between immune regulatory and effector responses in hepatitis b-infected participants enrolled in the hbrn's clinical trials (nct01369212 and nct01369199) to define natural history and treatment outcome.

aim 1. therapeutic hbv suppression will enhance antiviral immune effector responses and reduce immune inhibitory factors in participants with chronic hepatitis b. this study will also examine if antiviral therapy has a durable effect in host immune phenotype and define the immunological effect of interferon-alpha (ifnα) therapy in chronic hbv participants. aim 2. antiviral immune effector and regulatory responses before, during and/or after therapy can predict long term therapeutic response.

Eligibility criteria:
inclusion criteria: * ability to provide informed consent for participation in the ancillary study exclusion criteria: * children under 18 years of age * pregnant women * participants with anemia (hgb\<10 or hct\<30) * participants with active medical conditions such as congestive heart failure or chronic lung disease requiring oxygen, active coronary artery disease with unstable angina, sepsis and renal failure * participants with significant medical conditions, autoimmune disease or immunosuppression

Keywords: hepatitis b immunology hbv immune tolerant immune active